Baird raised the firm’s price target on Medpace (MEDP) to $613 from $491 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP:
- Medpace price target raised to $655 from $575 at Mizuho
- Medpace price target raised to $485 from $425 at Barclays
- Medpace Holdings Reports Strong Q3 2025 Results
- Medpace Holdings Inc. Reports Strong Q3 2025 Growth
- Medpace Holdings: Overvaluation Concerns Amid Growth Projections and Market Positioning